NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market Wednesday that its fourth-quarter revenues increased 32 percent to $1.1 million from $868,000, beating the consensus Wall Street estimate for revenues of $900,000.

The firm's product sales were $1 million for the three months ended Dec. 31, 2012, compared to $755,000 for the fourth quarter of 2011. License revenues were flat year over year at $113,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."